Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trialMaria Pouyiourou, Alwin Krämer, Bianca Kraft et al.|Nature Communications|2023Cited by 36
Validation of novel low-dose CT methods for quantifying bone marrow in the appendicular skeleton of patients with multiple myeloma: initial results from the [18F]FDG PET/CT sub-study of the Phase 3 GMMG-HD7 TrialChristos Sachpekidis, Antonia Dimitrakopoulou‐Strauss, Michael Hundemer et al.|European Journal of Nuclear Medicine and Molecular Imaging|2025Cited by 4
738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trialMaria Pouyiourou, A. Krämer, Timothy Wohlfromm et al.|Annals of Oncology|2022Cited by 3
Interdisciplinary guideline on diagnosis, therapy, and follow-up of adult patients with monoclonal gammopathy of undetermined significance or multiple myelomaPiechotta, Nicole Skoetz, Lukas John et al.|Unknown|2020Cited by 0
P-076 The impact of heterogeneous disease distribution on MRD detection in patients with relapsed multiple myelomaLukas John, Niels Weinhold, Martin Grözinger et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 0